Coming October 2: SITC releases abstract titles with each presenting author’s institution (nearly 1,300 last year). We’ll add them to this guide once they’re out.

AstraZeneca at SITC 2026

Nov 4–8, 2026 Phoenix, AZ ~6k attendees Website

AstraZeneca brings 2 presentations to SITC 2026 in Phoenix, and exhibits at Booth 801. Its program focuses on the regulation of new immuno-oncology agents and on how academic researchers can work with industry, including on grants. The most concrete topic is a look at its rilvegostomig bispecific antibody program.

OrganizationSITC 2026 Attendance
AstraZeneca
Cambridge, United Kingdom
Large pharma
Global biopharmaceutical company that discovers, develops and sells prescription medicines, with oncology among its main therapy areas.
Booth
Exhibiting at Booth 801
Fri, Nov 610:00am–2:00pm · 5:00pm–7:00pmSat, Nov 710:00am–2:00pm · 6:00pm–8:10pm
Workshop
Wed Nov 4
2:00pm–5:00pm
Biotech Regulatory Roundtable
  1. 2:00pm–2:10pmOpening Remarks: SITC Biotech Initiative: A Quest for 100 Novel Agents
  2. 2:10pm–2:55pmPanel Discussion 1: Conversations with FDA Oncology Leaders on Hot Topics
  3. 2:55pm–3:10pmNetworking Break
  4. 3:10pm–3:55pmPanel Discussion 2: Biomarker Discovery and Digital AI
  5. 3:55pm–4:10pmNetworking Break #2
  6. 4:10pm–4:55pmPanel Discussion 3: Regulatory Framework for New IO Agents
  7. 4:55pm–5:00pmClosing Remarks
Workshop
Wed Nov 4
2:10pm–2:55pm
Session
Wed Nov 4
4:10pm–4:55pm
Session
Thu Nov 5
12:00pm–1:30pm

Explore the full SITC 2026 dataset

Get in-depth attendee and institution profiles and research, to plan your meetings in Phoenix. Leave your work email and we’ll be in touch.

Privacy

Download the full SITC 2026 CSV

Leave your work email and we’ll be in touch. The CSV adds attendee names, roles and contact details to the company and session data shown here.

Privacy

Instantly find 20 buyers from AstraZeneca

Get a list of who you should contact, their contact info, and what to say.

Totally free and instant, no sign up necessary!

Not affiliated with or endorsed by the Society for Immunotherapy of Cancer (SITC). Submit a correction